Eton Pharmaceuticals Inc. (ETON)’s Financial Results Comparing With Kazia Therapeutics Limited (NASDAQ:KZIA)

We will be comparing the differences between Eton Pharmaceuticals Inc. (NASDAQ:ETON) and Kazia Therapeutics Limited (NASDAQ:KZIA) as far as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eton Pharmaceuticals Inc. N/A 0.00 18.36M -0.85 0.00
Kazia Therapeutics Limited N/A 0.00 N/A -0.90 0.00

Table 1 highlights Eton Pharmaceuticals Inc. and Kazia Therapeutics Limited’s top-line revenue, earnings per share and valuation.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Eton Pharmaceuticals Inc. 0.00% 0% 0%
Kazia Therapeutics Limited 0.00% -23.7% -16.4%


The Current Ratio and a Quick Ratio of Eton Pharmaceuticals Inc. are 8.1 and 8.1. Competitively, Kazia Therapeutics Limited has 2.4 and 2.4 for Current and Quick Ratio. Eton Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Kazia Therapeutics Limited.

Insider and Institutional Ownership

Institutional investors owned 0% of Eton Pharmaceuticals Inc. shares and 2.6% of Kazia Therapeutics Limited shares. 32.4% are Eton Pharmaceuticals Inc.’s share owned by insiders. Comparatively, 28.8% are Kazia Therapeutics Limited’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eton Pharmaceuticals Inc. -4.25% 0% 0% 0% 0% -2.72%
Kazia Therapeutics Limited -1.21% -9.19% -22.98% -45.92% -21.17% -15.47%

For the past year Eton Pharmaceuticals Inc.’s stock price has smaller decline than Kazia Therapeutics Limited.


Eton Pharmaceuticals Inc. beats on 5 of the 6 factors Kazia Therapeutics Limited.

Kazia Therapeutics Limited, a biotechnology company, develops anti-cancer drugs. It has three technologies, which include phosphoinositide 3-kinase inhibitors, superbenzopyran, and anti-tropomyosin. The company is developing GDC-0084, a novel targeted therapy that has completed Phase I clinical trial for the treatment of glioblastoma; Cantrixil, which is in Phase I clinical trials to treat ovarian cancer; and Trilexium, a novel therapy that is in early stage pre-clinical development for the treatment of various cancer types. It has collaboration agreement with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, and the University of Boston. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.